# BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

> **NCT07002216** · PHASE2 · RECRUITING · sponsor: **University of Miami** · enrollment: 48 (estimated)

## Conditions studied

- Hodgkin Lymphoma
- Advanced Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Etoposide
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Dacarbazine
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07002216
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2030-07-15
- **Final completion:** 2030-07-15
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07002216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07002216, "BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07002216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*